Figure 3.

Endogenous VEGF ₁₆₅ b is cytoprotective when pO ₂  < 2%. A. Trophoblasts were cultured in SFM (n = 5) ± Bevacizumab 25nM (to inhibit all VEGF-A isoforms, n = 7) or 50nM anti-VEGF-A₁₆₅b (clone 56/1, AbCam) to inhibit only VEGF-A₁₆₅b isoforms, n = 8) for 48 hours in a hypoxia chamber (<2%O₂) and cytotoxicity measured. (One way ANOVA, p = 0.0068, Dunnett’s Multiple Comparison Test). B. Trophoblasts were cultured in SFM ± 50nM anti-VEGF-A₁₆₅b in 21% 0₂ for 48 hours and cytotoxicity assayed. (Unpaired t test p = 0.6, n = 14). C. Cytotoxicity was not significantly increased in cells exposed to 25nM VEGF-A inhibitor bevacizumab (n = 23) compared with control conditions in SFM (n = 26, Unpaired T test with Welch correction, p > 0.05).